Can-Fite BioPharma Ltd.

Contributing Author

Recent Articles by Can-Fite BioPharma Ltd.

Jul-20	Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology CANF GlobeNewswire
Jul-14	Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer CANF GlobeNewswire
Jul-06	Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 CANF GlobeNewswire
Jul-01	Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease CANF +55.89% GlobeNewswire
Jun-26	Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology CANF -6.46% GlobeNewswire
Jun-22	Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson CANF GlobeNewswire
Jun-17	Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 CANF GlobeNewswire
Jun-02	Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism CANF GlobeNewswire
May-18	Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market CANF GlobeNewswire
May-13	Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy CANF +7.37% GlobeNewswire
Apr-30	Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months CANF +6.69% GlobeNewswire
Mar-30	Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 CANF GlobeNewswire
Mar-26	Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient CANF GlobeNewswire
Mar-17	Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance CANF GlobeNewswire
Mar-04	Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds CANF +20.40% GlobeNewswire
Mar-04	Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study CANF +20.40% GlobeNewswire
Feb-17	Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson CANF GlobeNewswire
Feb-09	Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy CANF GlobeNewswire
Feb-05	Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson CANF +5.20% GlobeNewswire
Jan-20	Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson CANF GlobeNewswire
Dec-26	Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction CANF +18.64% GlobeNewswire
Dec-23	Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change CANF CANF -25.03% GlobeNewswire
Dec-16	Can-Fite Provides Update on Clinical and Financial Status CANF +9.06% GlobeNewswire
Nov-26	Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference CANF GlobeNewswire
Nov-24	Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference CANF +11.99% GlobeNewswire
Nov-20	Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil CANF -6.95% GlobeNewswire
Nov-18	Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson CANF +5.00% GlobeNewswire
Sep-15	Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson CANF GlobeNewswire
Aug-28	Can-Fite Reports H1 2025 Financial Results and Clinical Update CANF GlobeNewswire
Jul-30	Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone CANF -5.26% GlobeNewswire
Jul-28	Can-Fite Announces Up To $15.0 Million Public Offering CANF -28.43% GlobeNewswire
Jul-28	Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia CANF -28.43% GlobeNewswire
Jun-16	Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston CANF +6.54% GlobeNewswire
May-05	Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis CANF GlobeNewswire

Can-Fite BioPharma Ltd.

Recent Articles by Can-Fite BioPharma Ltd.

Upgrade your Finviz experience